Last reviewed · How we verify
ABT-348 and carboplatin
At a glance
| Generic name | ABT-348 and carboplatin |
|---|---|
| Sponsor | AbbVie (prior sponsor, Abbott) |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- ABT-348 as Monotherapy or Combination With Carboplatin or Docetaxel to Treat Advanced Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ABT-348 and carboplatin CI brief — competitive landscape report
- ABT-348 and carboplatin updates RSS · CI watch RSS
- AbbVie (prior sponsor, Abbott) portfolio CI